Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for GKT137831

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GKT137831?

GKT137831 is an investigational drug.

There have been 4 clinical trials for GKT137831. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2019.

The most common disease conditions in clinical trials are Diabetes Mellitus, Idiopathic Interstitial Pneumonias, and Albuminuria. The leading clinical trial sponsors are Genkyotex SA, Genkyotex Innovation SAS, and University of Alabama at Birmingham.

There are six US patents protecting this investigational drug and forty-eight international patents.

Recent Clinical Trials for GKT137831
GKT137831 in IPF Patients With Idiopathic Pulmonary FibrosisUniversity of Alabama at BirminghamPhase 2
Bioequivalence StudyEurofins OptimedPhase 1
Bioequivalence StudyYork Bioanalytical SolutionPhase 1

See all GKT137831 clinical trials

Clinical Trial Summary for GKT137831

Top disease conditions for GKT137831
Top clinical trial sponsors for GKT137831

See all GKT137831 clinical trials

US Patents for GKT137831

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GKT137831   Start Trial Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (Plan-les-Ouates, CH)   Start Trial
GKT137831   Start Trial Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 Eastern Virginia Medical School (Norfolk, VA)   Start Trial
GKT137831   Start Trial Orvepitant for chronic cough therapy NeRRe Therapeutics Limited (Herts, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.